Novel synthesis of 4-or 6-substituted indirubin derivatives

Synthetic Communications

Volumn 40, Issue 21, 2010, Pages 3125-3134

  Zhang, Aiying ^a   Yu, Mingfeng ^a   Lan, Tian ^a   Liu, Zenglu ^a   Mao, Zhenmin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

4 substituted; Acid catalyzed; indirubin; steric hindrance

Indexed keywords

INDIRUBIN; INDIRUBIN DERIVATIVE; ISATIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; DRUG STRUCTURE; DRUG SYNTHESIS; OXIDATION;

EID: 77957902275     PISSN: 00397911     EISSN: 15322432     Source Type: Journal    
DOI: 10.1080/00397910903318591     Document Type: Article

References (22)

1. Xiao, Z. J.; Hao, Y. S.; Liu, B. C.; Qian, L. S. Indirubin and meisoindigo in the treatment of chromic myelogenous leukemia in China. Leuk. Lymph. 2002, 43, 1763-1768.
2. Ji, X. J.; Zhang, F. R.; Lei, J. L.; Xu, Y. T. Studies on the antineoplastic action and toxicity of synthetic indirubin. Acta Pharmaceutica Sinica. 1981, 16, 146-148.
3. Ji, X. J.; Liu, X. M.; Li, K.; Chen, R. H.; Wang, L. G. Pharmacological studies of meisoindigo: Absorption and mechanism of action. Biomed. Environ. Sci. 1991, 4, 332-337.
4. Yu, H.; Jove, R. The STATs of cancer\New molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97-105.
5. Kim, S.-A.; Kim, Y.-C.; Kim, S.-W.; Lee, S.-H.; Min, J.-J.; Ahn, S.-G.; Yoon, J.-H. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin. Cancer Res. 2007, 13, 253-259.
6. Tang, W.; Hemm, I.; Bertram, B. Recent development of antitumor agents from Chinese herbal medicines, part I: Low molecular compounds. Planta Med. 2003, 69, 97-108. (Pubitemid 36384491)
7. Libnow, S.; Methling, K.; Hein, M.; Michalik, D.; Harms, M.; Wende, K.; Flemming, A.; Köckerling, M.; Reinke, H.; Bednarski, P. J.; Lalk, M.; Langer, P. Synthesis of indirubin-N-glycosides and their anti-proliferative activity against human cancer cell lines. Bioorgan. Med. Chem. 2008, 16, 5570-5583.
8. Perabo, F. G. E.; Frössler, C.; Landwehrs, G.; Schmidt, D. H.; Von Rücker, A.; Wirger, A.; Müller, S. C. Indirubin-3-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res. 2006, 26(3A), 2129-2135.
9. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glyco-gen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 2004, 47, 935-946.
10. Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E. M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
11. Davies, T. G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; Endicott, J. A.; Noble, M. E. M. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A=indirubin-5-sulphonate. Structure 2001, 9, 389-397.
12. Marko, D.; Schätzle, S.; Friedel, A.; Genzlinger, A.; Zankl, H.; Meijer, L.; Eisenbrand, G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer. 2001, 84(2), 283-289.
13. Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E. M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclindependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
14. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y.-Z.; Mandekowi, E.-M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3b and CDK5=p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease, a property common to most CDK inhibitors. J. Biol. Chem. 2001, 276(1), 251-260.
15. Meijer, L.; Skaltsounis, A.-L.; Magiantis, P.; Polychromopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X. P.; Vonica, C. A.; Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10, 1255-1266.
16. Moon, M. J.; Lee, S. K.; Lee, J. W.; Song, W. K.; Kim, S. W.; Kim, J. I.; Cho, C.; Choi, S. J.; Kim, Y. C. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorgan. Med. Chem. 2006, 14, 237-246.
17. Tanoue, Y.; Hara, A.; Kai, N.; Sakata, K.; Hashimoto, M.; Nagai, T. A revised synthetic scheme of 6, 6-dibromoindirubin. J. Heterocycl. Chem. 2007, 44, 1135-1137.
18. Wu, Z.-L.; Aryal, P.; Lozach, O.; Meijer, L.; Guengerich, F. P. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. Chem. Biodivers. 2005, 2, 51-65.
19. Guengerich, F. P.; Sorrells, J. L.; Schmitt, S.; Krauser, J. A.; Aryal, P.; Meijer, L. Generation of new protein kinase inhibitors utilizing cytochrome P450 mutant enzymes for indigoid synthesis. J. Med. Chem. 2004, 47, 3236-3241.
20. Guha, S. K.; Mitra, A. K. Indigoid vat dyes of the isatin series, part XIII: 3-Indole-2-(6-bromo)thionaphthene-indoigos. J. Indian Chem. Soc. 1967, 44, 694-696.
21. Wang, Z. H.; Li, W. Y.; Li, F. L.; Zhang, L.; Hua, W. Y.; Cheng, J. C.; Yao, Q. Z. Synthesis and antitumor activity of 7-azaindirubin. Chin. Chem. Lett. 2009, 20, 542-544.
22. Wu, K.-M.; Zhang, M.-Y.; Fang, Z.; Huang, L. Potential antileukemic agents: Synthesis of derivatives of indirubin, indigo, and isoindigotin. Acta Pharm. Sin. 1985, 20, 821-826.